Denali Therapeutics fell 14% premarket on clinical hold for Alzheimer’s candidate

Tiger Newspress2022-01-13

Denali Therapeutics fell 14% in the pre-market after announcing a clinical hold imposed by the FDA for the company’s experimental therapy for Alzheimer’s disease, DNL919.

On Wednesday after the close, the regulator has informed the company via email that the DNL919 (ATV:TREM2) Investigational New Drug (IND) application had been placed on clinical hold.

An official clinical hold letter will be issued to Denali (DNLI) in this regard in about 30 days, the federal agency has added. The company plans to announce further updates on this development subject to its ongoing discussions with the regulator.

According to the therapeutic pipeline of the company, DNL919 (ATV:TREM2) is part of its Alzheimer’s program. Early this week, Denali (DNLI) said that subject to the FDA acceptance of its IND application, the company would begin first-in-human clinical trials for DNL919 in H1 2022.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
3